1. The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

3. Program Goal

4. ESC Guidelines

5. ACC/AHA Guidelines

6. RE-DUAL PCI Trial Design

7. RE-DUAL PCI ISTH Major or CRNM Bleeding

8. RE-DUAL PCI: Thromboembolic Events, Death, or Unplanned Revascularization

9. PIONEER AF-PCI Clinically Significant Bleeding

10. PIONEER AF-PCI Study Design

11. PIONEER AF-PCI MACE

12. RE-DUAL PCI TIMI Major Bleeding and ICH

13. Duration of Triple Therapy Options

14. Optimal OAC Dose Full Dose vs Reduced Dose

15. COMPASS Efficacy Outcomes in Stable CAD/PAD

16. ATLAS ACS 2-TIMI 51 Stent Thrombosis in ACS

17. P2Y12 Inhibitor in Antithrombotic Regimens Clopidogrel vs Newer Agents

18. RE-DUAL PCI Subgroup Analysis Clopidogrel vs Ticagrelor

19. Antithrombotic Strategies for Complex Patients With AF Following PCI

20. APPRAISE-2 Anticoagulant Therapy After ACS

21. Danish Registry: Thromboembolic and Bleeding Outcomes Following MI or PCI in Patients With AF

22. Antithrombotic Strategy Considerations

23. PIONEER AF-PCI Post Hoc Analysis Recurrent Hospitalization

24. ENTRUST-AF PCI Study Design

25. AUGUSTUS Study Design

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)